The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates.

PURPOSE To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. PATIENTS AND METHODS Twenty-one oncologists estimated the "median survival of a group of identical patients" for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression. RESULTS Median survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, ≤ one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101 U/L (HR = 2.8; P = .0002), Karnofsky performance status ≤ 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02). CONCLUSION Oncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.

[1]  B. Kiely,et al.  Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience , 2013, Supportive Care in Cancer.

[2]  B. Kiely,et al.  Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. , 2012, Lung cancer.

[3]  Enrique Espinosa,et al.  Development and validation of a prognostic nomogram for terminally ill cancer patients. , 2011, Journal of the National Cancer Institute.

[4]  V. Baracos,et al.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer , 2011, British Journal of Cancer.

[5]  B. Kiely,et al.  How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Pavlakis,et al.  High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy , 2010, Clinical Cancer Research.

[7]  E. Abdalla,et al.  Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy , 2009, Annals of Surgical Oncology.

[8]  S. Payne,et al.  Advanced cancer patients’ prognostic information preferences: a review , 2009, Palliative medicine.

[9]  Paul Glare,et al.  Predicting survival in patients with advanced disease. , 2008, European journal of cancer.

[10]  D. Gomez,et al.  Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma , 2008, Journal of surgical oncology.

[11]  Shigemi Matsumoto,et al.  The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer , 2008, Oncology.

[12]  H. Malik,et al.  Preoperative Prognostic Score for Predicting Survival After Hepatic Resection for Colorectal Liver Metastases , 2007, Annals of surgery.

[13]  I. Hickie,et al.  Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. , 2007, The Lancet. Oncology.

[14]  M. Stockler,et al.  Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer , 2005, British Journal of Cancer.

[15]  M. ChB.,et al.  Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer , 2005, Journal of surgical oncology.

[16]  N. Christakis,et al.  Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Özdoğan,et al.  A simple and accurate prediction model to estimate the intrahospital mortality risk of hospitalised cancer patients , 2004, International journal of clinical practice.

[18]  T. Chiu,et al.  Prediction of survival in terminal cancer patients in Taiwan: constructing a prognostic scale. , 2004, Journal of pain and symptom management.

[19]  Phyllis N Butow,et al.  Cancer patient preferences for communication of prognosis in the metastatic setting. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Paul Glare,et al.  A systematic review of physicians' survival predictions in terminally ill cancer patients , 2003, BMJ : British Medical Journal.

[21]  F. Pannuti,et al.  Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  P. Craft,et al.  Self-rated health as a predictor of survival among patients with advanced cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Esteva,et al.  Terminal cancer. duration and prediction of survival time. , 2000, European journal of cancer.

[24]  A. Vigano,et al.  Survival prediction in terminal cancer patients: a systematic review of the medical literature , 2000, Palliative medicine.

[25]  N. Christakis,et al.  Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study , 2000, BMJ : British Medical Journal.

[26]  M. Maltoni,et al.  A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. , 1999, Journal of pain and symptom management.

[27]  T. Morita,et al.  Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. , 1999, Japanese journal of clinical oncology.

[28]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[29]  Lh Heyse-Moore,et al.  Can doctors accurately predict the life expectancy of patients with terminal cancer? , 1987 .

[30]  A. Feinstein Symptoms as an Index of Biological Behaviour and Prognosis in Human Cancer , 1966, Nature.

[31]  H. Malik,et al.  Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[32]  Sung Hoon Kim,et al.  Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment , 2008, Cancer Immunology, Immunotherapy.

[33]  M. Faris Clinical estimation of survival and impact of other prognostic factors on terminally ill cancer patients in Oman , 2002, Supportive Care in Cancer.